HIKMA Pharmaceuticals PLC — Director's Dealing 2014

Mar 24, 2014

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 0011D

Hikma Pharmaceuticals Plc

24 March 2014

Hikma Pharmaceuticals PLC - Vesting of 2011 LTIP

LONDON, 24 March 2014: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) announces that the following Persons Discharging Managerial Responsibility ("PDMR") have received conditional share awards which vested on 24 March 2014 under the 2005 Long Term Incentive Plan ("LTIP") and were automatically exercised by operation of the conditional award and vesting process. The exercise price under the LTIP is £nil. The persons concerned have retained all the shares exercised.

In accordance with DTR 3.1.2R and s.793 of the Companies Act 2006, Hikma announces that the following transactions took place in London over the Company's Ordinary Shares of 10p each as detailed below.

PDMR	Type of Transaction	Exercised	Date		Price	Shares Disposed	Remaining Holding
Bassam Kanaan	Vesting of LTIP 2011	35,432 (0.02% ISC)	24 March 2014		£16.23	Nil	503,566 (0.25% ISC)
Michael Raya	Vesting of LTIP 2011	31,776 (0.02% ISC)	24 March 2014		£16.23	Nil	76,160 (0.04% ISC)
Riad Mishlawi	Vesting of LTIP 2011	19,067 (0.01% ISC)	24 March 2014		£16.23	Nil	79,327 (0.04% ISC)
Khalid Nabilsi	Vesting of LTIP 2011	26,011 (0.01% ISC)	24 March 2014		£16.23	Nil	196,858 (0.10% ISC)

- ENDS -

Enquiries                                                                                                                                      

Peter Speirs                                                                          +44 20 7399 2760

Company Secretary, Hikma Pharmaceuticals PLC

About Hikma

Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products.  Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe.  In 2013, Hikma achieved revenues of $1,365 million and profit attributable to shareholders of $212 million. 

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSBGGDXIBDBGSS